In summary, this study highlights that a rapid early decline in BCR::ABL1 transcript levels is a strong predictor of deep molecular remission in pediatric CML-CP. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.